Persistence of Immune Response Six Years After One Dose of 9vHPV Vaccine Among Male and Female Students
Canadian Immunization Research Network
300 participants
Sep 23, 2025
INTERVENTIONAL
Conditions
Summary
Since the 2019-2020 school year, the province of Quebec (Canada) has been administering one dose of nonavalent (9vHPV) vaccine to students of all genders in Grade 4 of elementary school through the school-based program. Little data on the immunogenicity (antibody production) and long-term efficacy of a single dose of the vaccine are available, particularly in boys. The primary objective of this study is to assess the persistence of HPV antibodies six years after the administration of a single dose of the 9vHPV vaccine to students aged 9 to 11 years in Grade 4 in 2019-2020. The study will be conducted at the CHU de Québec-Université Laval research center. Recruitment is conducted through school service centers in the Quebec City region. Youth who received only a single dose of the 9vHPV vaccine at the ages of 9-11 in 2019-2020 will be eligible to participate. Approximately 300 youth will take part in this study: 150 girls and 150 boys. Participants will have to answer few questions about their health to ensure their eligibility for the study. For eligible participants consenting to participate a 10 ml (\<1 tablespoon) blood sample will be taken.
Eligibility
Inclusion Criteria3
- Have received a single dose of 9vHPV vaccine at ages 9-11 during the school year 2019-2020;
- Not have received any other HPV vaccine doses;
- Be able to consent to the study.
Exclusion Criteria1
- Immunosuppressed (at recruitment or when immunized).
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
One dose HPV nonavalent vaccine
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07156084